16.23
+0.56(+3.57%)
Currency In USD
| Previous Close | 15.67 |
| Open | 15.69 |
| Day High | 16.52 |
| Day Low | 15.56 |
| 52-Week High | 32.1 |
| 52-Week Low | 12.72 |
| Volume | 2.2M |
| Average Volume | 1.46M |
| Market Cap | 2.83B |
| PE | -5.71 |
| EPS | -2.84 |
| Moving Average 50 Days | 15.91 |
| Moving Average 200 Days | 18.11 |
| Change | 0.56 |
If you invested $1000 in Immunovant, Inc. (IMVT) since IPO date, it would be worth $1,631.16 as of September 29, 2025 at a share price of $16.23. Whereas If you bought $1000 worth of Immunovant, Inc. (IMVT) shares 5 years ago, it would be worth $445.27 as of September 29, 2025 at a share price of $16.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
GlobeNewswire Inc.
Sep 03, 2025 4:57 PM GMT
First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 les
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
GlobeNewswire Inc.
Apr 21, 2025 11:00 AM GMT
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader str
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies
GlobeNewswire Inc.
Mar 19, 2025 11:45 AM GMT
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64%